Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapy.

•A new series of imidazolinone fatty acid synthase inhibitors.•Crystal structure shows binding to the fatty acid synthase ketoreductase domain.•Strong antiproliferative activity in several cancer cell lines.•Favorable ADME properties and significant oral exposure in mice.